trial

Varenicline Effects In Schizophrenic Smokers

NCTId NCT00548470
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 14 (actual)
Sponsored by Nathan Kline Institute for Psychiatric Research
Primary completion 2009-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
14 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2007-06
Primary completion
2009-09
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Varenicline

Sponsors

Nathan Kline Institute for Psychiatric ResearchLead Sponsor
University of Illinois at ChicagoCollaborator

Investigators

1
Robert C. Smith, MD, PhDPrincipal Investigator

Sites

1 total
New York, United States

Facts & assertions

4 sourced
Enrollment
14
Phase
PHASE4
Primary Completion Date
2009-09
Status
COMPLETED
relationships
The graph out of here
drug
Varenicline
drug
lead_sponsor
Nathan Kline Institute for Psychiatric Research
company
collaborator
University of Illinois at Chicago
company
indication
Nicotine Dependance
indication
Tobacco Use Disorder
indication
Cigarette Smoking
indication
investigator
Robert C. Smith, MD, PhD
person